Alok Srivastava/LinkedIn, Khaled Musallam/LinkedIn
May 6, 2026, 02:23
Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on LinkedIn:
“When the worlds of thalassemia and hemophilia converge, impactful advances are inevitable.
Delighted to welcome Prof Alok Srivastava as Visiting Professor, Consultant Hematologist, and Deputy Chief of Cell and Gene Therapy and Hematology at Burjeel Cancer Institute.
Excited for what lies ahead as we build robust services and bring forward innovative therapies for patients with blood disorders.”
More posts featuring Khaled Musallam on Hemostasis Today.
-
Jun 26, 2026, 13:40Caylynn Carls: Why Genetic Counseling Matters in Hemophilia Treatment
-
Jun 26, 2026, 13:25Ángel Cabrera: Clotting Disorders Behind Heavy Menstrual Bleeding
-
Jun 26, 2026, 13:02Turid Kjellevold: The Critical Role of Timely Hemostasis Testing
-
Jun 26, 2026, 10:59Wolfgang Miesbach: How Clonal Hematopoiesis May Explain Age-Related Mitochondrial Mutations
-
Jun 26, 2026, 10:52Chinua Onyebuchi: The Future of Stroke Care in Africa Lies in Strong Health Systems
-
Jun 26, 2026, 10:35Habtamu Milkias Wolde: New Insights into Stroke and Traumatic Brain Injury from Global Burden of Disease Data
-
Jun 26, 2026, 10:19Rytis Masiliūnas: Atrial Fibrillation and Stroke Care Disparities Across the Baltic Region
-
Jun 26, 2026, 10:11Kayla Kilani: First-Ever CT Perfusion Scan Performed Inside a Mobile Stroke Unit
-
Jun 26, 2026, 07:38Baraa Nassar: High Clinical Suspicion Is Essential for Early Diagnosis of CVST